PTPRD

Across TCGA pan-cancer cohorts, PTPRD Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated PTPRD data layer compared with 28 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher PTPRD Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PTPRD expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

ACC, UCEC, and THYM are the cancer types where PTPRD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.133	0.686	.004	24	view →
UCEC	DFS	Median	II,III,IV	0.776	0.302	.019	16	view →
THYM	OS	Median	All	0.186	0.931	<.001	15	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
SARC	DFS	Median	All	0.159	0.613	.015	6	view →
SKCM	OS	Median	IV	0.415	0.861	.014	5	view →
KIRP	OS	Median	All	0.786	0.949	.005	4	view →
LUAD	OS	Median	III,IV	0.512	0.321	.011	4	view →
LUSC	DFS	Median	III,IV	0.193	0.647	.001	3	view →
ESCA	DFS	Median	All	0.775	0.502	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

PTPRD–ACC (OS)

Open the ACC breakdown →